Rifampin NDC 70954-893

NDC codes

FDA NDC Directory

Product NDC (as listed)70954-893Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70954-0893Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
70954-893-10	70954089310	30 CAPSULE in 1 BOTTLE (70954-893-10)Marketed from Jul 20, 2026
70954-893-20	70954089320	60 CAPSULE in 1 BOTTLE (70954-893-20)Marketed from Jul 20, 2026
70954-893-30	70954089330	100 CAPSULE in 1 BOTTLE (70954-893-30)Marketed from Jul 20, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Rifampin
Generic name (nonproprietary): rifampin
Active ingredients: Rifampin — 300 mg/1
Dosage form: Capsule
Route: Oral
Labeler: ANI Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 219918
Marketing start: Jul 20, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Rifamycins (Chemical structure)
Identifiers: Product ID 70954-893_b389b1a3-672f-47e3-916c-4a9c044b211bSPL ID b389b1a3-672f-47e3-916c-4a9c044b211bSPL set ID b389b1a3-672f-47e3-916c-4a9c044b211bRxCUI 198201, 198202UNII VJT6J7R4TRUPC 0370954893103, 0370954893301, 0370954892205, 0370954893202
Pharmacologic class: Rifamycin Antibacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470954089310 followed by a unit qualifier and the quantity

Package 70954-0893-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 10, 2024.

Indications (excerpt from the label)

INDICATIONS & USAGE In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 219918

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 219918
Product	Strength	Form · route	Labeler	Product NDC
Rifampin	Rifampin 150 mg/1	CapsuleOral	ANI Pharmaceuticals, Inc.	70954-892